Faricimab outperforms anti-VEGF Drugs in DME and AMD Treatment by improving central subfoveal thickness
In the industrialized world, Neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) cause blindness. Faricimab, launched in the US in January 2022, treats diabetic macular edema and wet age-related macular degeneration. Based on evidence from Systematic reviews, anti-VEGF agents’ are advantageous in AMD and DME compared to other therapies. In a study published […]